期刊文献+

VEGF在乳腺癌组织与血清中的表达及临床意义 被引量:4

Expression of VEGF in Breast Cancer Tissue and its Clinical Significance
原文传递
导出
摘要 目的探讨血管内皮生长因子(VEGF)与乳腺癌发生、发展及淋巴结转移的关系。方法免疫组化方法测定不同组织学类型乳腺癌组织中VEGF水平;用双抗体夹心酶联免疫吸附法(ELISA)测定血清中VEGF水平。结果 1)VEGF表达阳性率随着乳腺癌组织学分级增高而逐渐增高,淋巴结转移的乳腺癌组VEGF阳性表达率为92.86%(26/28),无淋巴结转移的乳腺癌组VEGF阳性表达率为81.82%(18/22);2)正常对照组和良性乳腺癌组血清VEGF水平比较,两组间差异无统计学意义(P>0.05);正常对照组与恶性乳腺癌组进行比较,差异有统计学意义(P<0.01);良性乳腺癌组与恶性乳腺癌组比较,其VEGF的浓度较恶性乳腺癌患者低,差异有统计学意义(P<0.01)。结论 VEGF在乳腺癌中高表达,提示其可能与乳腺癌的恶性进展有关;VEGF与乳腺癌淋巴结转移有关,检测VEGF含量对预测乳腺癌淋巴结转移具有重要意义。 Objective To investigate the expressions of vascular endothelial growth factor (VEGF) in serum and breast cancer tissues, and to explore their relationships with the occurrence, development and lymph node metastasis of the cancer. Methods VEGF expression in the breast cancer tissue of different histological types was determined by immunohistochemistry, and VEGF level in serum was detected by ELISA. Results The positive rate of VEGF expression was increased with the progress of the histological grade of the breast cancer. The positive rate of VEGF in the lymph node metastasis group was 92.86% (26/28), while that in the non lymph node metastasis group was 81.82% (18/22). The serum VEGF level in the lymph node metastasis group was significantly higher than that in the non lymph node metastasis group (P 〈 0.05). The serum VEGF level was not significantly different between the nomml control group and the benign breast cancer group (P ~ 0.05), while that in the malignant breast cancer group was significantly higher than those in the other two groups (P 〈 0.01). Con- clusions VEGF is highly expressed in breast cancer. It may correlate with the malignancy and node metastasis of the cancer. Detection of VEGF is of important significance in predicting node metastasis of breast cancer.
出处 《实用预防医学》 CAS 2012年第8期1245-1247,共3页 Practical Preventive Medicine
关键词 血管内皮生长因子 乳腺癌 免疫组织化学 VEGF Breast Cancer Immunohistochemistry
  • 相关文献

参考文献13

  • 1Oliveira VM, Aldrighi JM, Bagnoli F. Evidence of the action of bisphosphonates in the prevention of breast eancer[J]. Rev Assoc Med Bras, 2011, 57(1): 7-8. 被引量:1
  • 2李恩孝,吴胤瑛,施璠.靶向VEGF治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,14(3):370-372. 被引量:6
  • 3Suzuki K, Hagashy N, Miyamoto Y, et al. Expression of vascular per- meability factor vascular endothelial growth factor in human hepatocellular carcinoma J[J]. Cancer Res, 1996, 56(13) : 3004- 3009. 被引量:1
  • 4Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma; correlation with VEGF - A and MTA1 expression [J ]. Tumour Biol, 2011, 32 ( 1 ) : 23 - 32. 被引量:1
  • 5郭仁德.血管内皮生长因子与肿瘤的研究进展[J].医学综述,2002,8(2):68-70. 被引量:12
  • 6Heer N, Kumar H, Read JR, et al. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen recep- tor status[J]. Clin Cancer Res, 2001, 7:3491-3494. 被引量:1
  • 7Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF- A and MTA1 expression [ J ]. Tumour Biol, 2011, 32 ( 1 ) : 23 - 32. 被引量:1
  • 8Derleth C, Mayer IA. Antiangiogenic therapies in early- stage breast cancer[J]. Clin Breast Cancer, 2010, 10(Suppl 1) : E23 - 31. 被引量:1
  • 9Das S, Ladell DS, Podgrabinska S, et al. Vascular endothelial growth factor- C induces lymphangitie careinomatosis, an extremely aggressive form of lung metastases[J], Cancer Res, 2010, 70(5): 1814- 1824. 被引量:1
  • 10Ran S, Volk L, Hall K, et al. Lymphartgiogenesis and lymphatic metastasis in breast cancer[J]. Pathophysiology, 2010,17(4) : 229 - 251. 被引量:1

二级参考文献47

  • 1赵军,刘叙仪,张青云,蒋薇.晚期非小细胞肺癌患者外周血VEGF和bFGF及MMP-9水平与预后的关系[J].中华肿瘤杂志,2005,27(11):676-679. 被引量:30
  • 2leffler SG,Chew FS.CT-guided percutaneous biopsy of sclerotic bone lesions:diagnostic yield and accuracy[J].AJR AM J Roentgenol,1999,172:1389-1392. 被引量:1
  • 3Padro T,Ruiz S,Bieker R,et al.Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia[J].Blood,2000,95(8):2637-2644. 被引量:1
  • 4Harlozinska A.Progress in molecular mechanisms of tumor metastasis and angiogenesis[J].Anticancer Res,2005,25:3327-3333. 被引量:1
  • 5Bellon G,Martiny L,Robinet A.Matrix metalloproteinases and matrikines in angiogenesis[J].Crit Rev Oncol Hematol,2004,49 (3):203-220. 被引量:1
  • 6Iruela-Arispe ML,Luque A,Lee N.Thrombospondin modules and angiogenesis[J].Int J Biochem Cell Biol,2004,36 (6):1070-1078. 被引量:1
  • 7Brekken RA,Ovetholser JP,Stastny VA,et al.Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice[J].Cancer Res,2000,60 (18):5117-5124. 被引量:1
  • 8Zhang L,Hannay JA,Liu J,et al.Vascular endothelial growth factor overexpression by soft tissue sercoma cells:implications for tumor growth,metastasis and chemoresistance[J].Cancer Res,2006,66 (17):8770-8778. 被引量:1
  • 9Kitamura M,Toi M,Arai K,et al.Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients[J].Oncol Rep,1998,5(6):1419-1424. 被引量:1
  • 10Alexandra G,Efthimios S,Rolf B,et al.The angiogenic "Vascular endothelial growth factor/flk-1 (KDR) receptor" pathway in patients with endometrial carcinoma[J].Cancer,2001,92 (10):2569-2577. 被引量:1

共引文献26

同被引文献34

  • 1Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000 [ J ]. Int J cancer, 2001,94 (2) :153 - 155. 被引量:1
  • 2Bauer KR, Brown M, Cress B.D, et al. Descriptive analysis d estrogen receptor ( ER )-negative, progesterone receptor (PB)-negative,and HEB2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry[J]. Cancer,2007, 109(9) :1 721 -1 728. 被引量:1
  • 3Haffty BG,Yang Q,Reiss M,et al. Locovegional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer [ J ]. J Clin Oncol, 2006,24 (36) : 5 652 -5 657. 被引量:1
  • 4Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer:cllnical features and patterns of recurrence [J]. Clin Cancer Res,2007,13(15 Ptl) :4 429 -4 434. 被引量:1
  • 5Cleator S, HeUer W, Coombes RC. Triple-negative breast cancer: therapeutic options[ J ]. Lancet Oncol,2007,8 (3) : 235 - 244. 被引量:1
  • 6Rakha EA,EI-Sayed ME,Green AR,et al. Prognostic mark- ers in triple-negative breast cancer [ J ]. Cancer, 2,007,109 (1) :25 -32. 被引量:1
  • 7Linderholm BK,Lindahl T,Holmberg L,et al. The expres- sion of vascular endothelial growth factor correlates with mutunt p53 and poor prognosis in human breast cancer [J]. Cancer Res,2001,61(5) :2 256 -2 260. 被引量:1
  • 8Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expres- sion in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression [ J ]. Turnout Biol, 2011,32 (1) :23 -32. 被引量:1
  • 9Tischkowitz M,Brunet JS,Begin LR,et al. Use of immuno- histochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer,2007, (7) :134. 被引量:1
  • 10Linderholm BK, Hellborg H,Johhanson U, e al . Significantly higher levels of vascular endothelial factor(VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer[J]. Ann Oncol ,2009,20(4):1639-1646. 被引量:1

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部